The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | Rational for HER3-targeting in NRG1 fusion-positive NSCLC
Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, explains the rational for targeting HER3 in neuregulin 1 (NRG1) fusion-positive non-small cell lung cancer (NSCLC). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
